Where are Daiichi Sankyo, Inc. headquarters?
Daiichi Sankyo, Inc. headquarters are in Bernards, New Jersey, United States.
How many employees does Daiichi Sankyo, Inc. have?
Daiichi Sankyo, Inc. has 4169 employees.
What sector does Daiichi Sankyo, Inc. operate in?
Daiichi Sankyo, Inc. is in pharma sector.
Is Daiichi Sankyo, Inc. a public company?
Yes, Daiichi Sankyo, Inc. is a public company.
What does Daiichi Sankyo, Inc. Do ?
Daiichi sankyo, inc. headquartered in basking ridge, new jersey, is the u.s. subsidiary of daiichi sankyo, co., ltd. and a member of the daiichi sankyo group. commercial operations, research & development and several global functions operate out of headquarters. our team of more than 1,400 u.s. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. we currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioid-induced constipation, iv iron therapy and metastatic melanoma. with over 100 years of scientific expertise and a presence in more than 20 countries, daiichi sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. in addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the group’s 2025 vision to become a “global pharma innovator with a competitive advantage in oncology,” daiichi sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.
What does Daiichi Sankyo, Inc. specialize into ?
Daiichi Sankyo, Inc. specialises into Daiichi Sankyo, Inc. Currently Markets Therapies In Hypertension, Thrombotic Disorders, Stroke Risk Reduction, Dyslipidemia, Diabetes, Acute Coronary Syndrome, Opioid-induced Constipation, Iv Iron Therapy And Metastatic Melanoma. In Addition, Our Research And Development Is Primarily Focused On Bringing Forth Novel Therapies In Oncology, Including Immuno-oncology, With Additional Focus On New Horizon Areas, Such As Pain Management, Neurodegenerative Diseases, Heart And Kidney Diseases, And Other Rare Diseases. Pp-us-np-0246 08/17
Who is the CEO of Daiichi Sankyo, Inc. ?
We do not have the information about the CEO of Daiichi Sankyo, Inc.. Our systems are trying to find it, we will update it as soon as we have it.
Try Mr. E's contact finder tool and fetch direct mobile numbers of decision-makers of all companies globally. Grow your sales now.
Free Trial with 5 contacts. No Credit Card Required. One-click Signup.